Detalles de la búsqueda
1.
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
Breast Cancer Res Treat
; 201(2): 151-159, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37338729
2.
CLytA-DAAO Chimeric Enzyme Bound to Magnetic Nanoparticles. A New Therapeutical Approach for Cancer Patients?
Int J Mol Sci
; 22(3)2021 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33540681
3.
Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer.
Breast Cancer Res Treat
; 175(1): 129-139, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30673970
4.
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
Breast Cancer Res Treat
; 176(2): 377-386, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31041683
5.
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Breast Cancer Res Treat
; 177(1): 115-125, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31152327
6.
Lack of cytomegalovirus detection in human glioma.
Virol J
; 14(1): 216, 2017 11 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29116009
7.
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Breast Cancer Res Treat
; 156(1): 81-9, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26909792
8.
Defining breast cancer intrinsic subtypes by quantitative receptor expression.
Oncologist
; 20(5): 474-82, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25908555
9.
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Breast Cancer Res
; 16(2): R38, 2014 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24725534
10.
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
Lancet Oncol
; 14(1): 72-80, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23246022
11.
Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.
Clin Transl Oncol
; 26(7): 1539-1548, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38336982
12.
Medical oncology workload, workforce census, and needs in Spain: two nationwide studies by the Spanish Society of medical oncology.
Clin Transl Oncol
; 26(1): 98-108, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37316754
13.
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.
Clin Transl Oncol
; 2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38578537
14.
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis.
Breast Cancer Res
; 15(6): R105, 2013 Nov 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-24192331
15.
Adjuvant docetaxel for high-risk, node-negative breast cancer.
N Engl J Med
; 363(23): 2200-10, 2010 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-21121833
16.
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
Breast Cancer Res Treat
; 138(2): 457-66, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23423445
17.
Bevacizumab in advanced breast cancer: a new model for the assessment of activity in non-first-line treatment regimens.
Anticancer Drugs
; 24(9): 975-9, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23863615
18.
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis.
Clin Transl Oncol
; 25(4): 941-958, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36417083
19.
Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section.
Clin Transl Oncol
; 25(3): 796-802, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36418642
20.
The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review.
Clin Transl Oncol
; 25(2): 417-428, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36153763